| Adjuvant icotinib for resected EGFR-mutated stage II-IIIA non-small-cell lung cancer (ICTAN, GASTO1002): a randomized comparison study.PMID 40866342 · Signal Transduct Target Ther |
2025-Aug-28 |
2 | 2 | 2 | 4 |
质量警告 |
| The immune signatures predict gastric/gastroesophageal junction cancer response to first-line anti-PD-1 blockade or chemotherapy.PMID 40851062 · BMC Cancer |
2025-Aug-25 |
3 | 11 | 11 | 19 |
质量警告 |
| Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study.PMID 40623279 · J Clin Oncol |
2025-Aug-20 |
1 | 6 | 6 | 8 |
质量警告 |
| Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results.PMID 40127397 · Blood |
2025-Aug-07 |
1 | 2 | 2 | 5 |
质量警告 |
| Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial.PMID 40769977 · Signal Transduct Target Ther |
2025-Aug-06 |
2 | 2 | 2 | 2 |
质量警告 |
| Adjuvant Aspirin Treatment in PIK3CA-Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial.PMID 40067142 · Clin Cancer Res |
2025-Aug-01 |
2 | 2 | 2 | 4 |
提取完成 |
| First-line serplulimab plus chemotherapy in extensive-stage small-cell lung cancer: Updated results and biomarker analysis from the ASTRUM-005 randomized clinical trial.PMID 40440184 · Cancer Commun (Lond) |
2025-Aug |
1 | 2 | 2 | 8 |
提取完成 |
| Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study.PMID 40448579 · J Clin Oncol |
2025-Aug |
3 | 5 | 5 | 7 |
质量警告 |
| Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial.PMID 40450141 · Nat Med |
2025-Aug |
2 | 4 | 4 | 5 |
质量警告 |
| Efficacy and safety of oral decitabine/cedazuridine in the chronic myelomonocytic leukaemia subpopulations from phase 2 and 3 studies.PMID 40524338 · Br J Haematol |
2025-Aug |
1 | 3 | 3 | 6 |
提取完成 |
| Transcriptomic Analysis of Localized High-risk Prostate Cancer Improves Prognostication and Identifies Benefit from Adding Docetaxel to Definitive Radiotherapy with Androgen Suppression in the NRG Oncology/RTOG 0521 Phase 3 Trial.PMID 40675873 · Eur Urol Oncol |
2025-Aug |
1 | 2 | 2 | 6 |
质量警告 |
| Short-duration preoperative endocrine therapy alters molecular profiles to predict favourable outcome in ER+/HER2+ early breast cancer: a POETIC translational study.PMID 40683772 · EBioMedicine |
2025-Aug |
2 | 6 | 6 | 15 |
质量警告 |
| Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: results from the NAPOLI 3 trial.PMID 40763412 · ESMO Open |
2025-Aug |
2 | 2 | 2 | 4 |
提取完成 |
| Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study.PMID 40009500 · Blood |
2025-Jul-31 |
1 | 1 | 1 | 2 |
提取完成 |
| The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy.PMID 40233321 · Blood |
2025-Jul-31 |
1 | 1 | 1 | 1 |
质量警告 |
| Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial.PMID 40580808 · Eur J Cancer |
2025-Jul-25 |
2 | 6 | 6 | 11 |
质量警告 |
| Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial.PMID 40691143 · Nat Commun |
2025-Jul-21 |
2 | 5 | 5 | 9 |
质量警告 |
| Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin.PMID 40513032 · N Engl J Med |
2025-Jul-17 |
1 | 1 | 1 | 2 |
提取完成 |
| Pretreatment and on-treatment ctDNA and tissue biomarkers predict recurrence in patients with stage IIIB-D/IV melanoma treated with adjuvant immunotherapy: CheckMate 915.PMID 40645660 · J Immunother Cancer |
2025-Jul-11 |
3 | 11 | 11 | 36 |
质量警告 |
| Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE.PMID 40408605 · J Clin Oncol |
2025-Jul-10 |
1 | 2 | 2 | 4 |
提取完成 |
| Survival and Quality of Life After Isolated Hepatic Perfusion With Melphalan as a Treatment for Uveal Melanoma Liver Metastases: Final Results From the Phase III Randomized Controlled Trial SCANDIUM.PMID 38420778 · Ann Surg |
2025-Jul-01 |
2 | 6 | 6 | 12 |
质量警告 |
| Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer.PMID 40215429 · J Clin Oncol |
2025-Jul |
2 | 4 | 4 | 8 |
提取完成 |
| Association of statin use on survival outcomes of patients with early-stage HER2-positive breast cancer in the APHINITY trial.PMID 40293644 · Breast Cancer Res Treat |
2025-Jul |
1 | 3 | 3 | 5 |
质量警告 |
| Atezolizumab plus bevacizumab and chemotherapy in metastatic nonsquamous NSCLC: the randomized double-blind phase 3 IMpower151 trial.PMID 40379995 · Nat Med |
2025-Jul |
1 | 2 | 2 | 4 |
提取完成 |
| Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial.PMID 40408613 · J Clin Oncol |
2025-Jul |
3 | 6 | 6 | 11 |
质量警告 |
| Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial.PMID 40467898 · Nat Med |
2025-Jul |
2 | 4 | 3 | 5 |
部分完成 |
| Pembrolizumab plus chemotherapy with or without bevacizumab in East Asian participants with persistent, recurrent, or metastatic cervical cancer: results from KEYNOTE-826 final analysis.PMID 40590325 · J Gynecol Oncol |
2025-Jul |
2 | 4 | 4 | 8 |
提取完成 |
| Transcriptomic Predictors of Survival for Palbociclib + Endocrine Therapy Versus Capecitabine in Aromatase Inhibitor-Resistant Breast Cancer From the GEICAM/2013-02 PEARL Trial.PMID 40632974 · JCO Precis Oncol |
2025-Jul |
2 | 5 | 5 | 16 |
提取完成 |
| Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer.PMID 40444708 · N Engl J Med |
2025-Jun-26 |
2 | 2 | 2 | 6 |
提取完成 |
| Abemaciclib plus non-steroidal aromatase inhibitor or fulvestrant in women with HR+/HER2- advanced breast cancer: Final results of the randomized phase III MONARCH plus trial.PMID 39385327 · Chin Med J (Engl) |
2025-Jun-20 |
2 | 4 | 4 | 7 |
质量警告 |